2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
39
Leukemia, Myeloid, Acute
35
Myelodysplastic Syndromes
33
Multiple Myeloma
30
Lymphoma, Non-Hodgkin
29
Hodgkin Disease
28
Graft vs Host Disease
26
Leukemia, Lymphocytic, Chronic, B-Cell
25
Lymphoma
24
Leukemia
24
Hematologic Neoplasms
20
Neoplasms
18
Lymphoma, Mantle-Cell
18
Sarcoma
17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Breast Neoplasms
17
Tuberous Sclerosis
15
Myeloproliferative Disorders
15
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma, Follicular
14
Burkitt Lymphoma
14
Waldenstrom Macroglobulinemia
13
Lymphoma, B-Cell, Marginal Zone
13
Recurrence
12
Neoplasm Metastasis
12
Carcinoma, Non-Small-Cell Lung
12
Prostatic Neoplasms
11
Primary Myelofibrosis
11
Melanoma
11
Leukemia, Myelomonocytic, Chronic
11
Interventions
Radiotherapy, Intensity-Modulated
2
Cisplatin
2
pembrolizumab
1
Sirolimus
1
Nimorazole
1
Everolimus
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Otorhinolaryngologic Diseases
×
Sirolimus
×
Clear all
NCT01490476
2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
10 enrolled